Loading
A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer is a phase 3 interventional study registered as NCT06296706 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 630 participants planned, started 2024-02-27 and due to reach its primary completion in 2026-06-01. Interventions recorded: Docetaxel for injection (Albumin-bound) and Taxotere (docetaxel).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/